Polarean Imaging

Polarean Imaging is a revenue-generating, commercial-stage company pioneering hyperpolarized xenon-129 MRI for functional lung imaging. Its core achievement is the FDA approval in December 2022 of XENOVIEW™, the first and only hyperpolarized MRI contrast agent approved in the United States. The technology addresses significant limitations in current lung imaging by providing quantitative, regional lung function data without ionizing radiation. Polarean aims to serve the vast unmet need in chronic respiratory diseases, targeting a global patient population exceeding 500 million.

Hyperpolarized xenon-129 (129Xe) MRI platform for functional lung imaging. Comprises a polarizer device, xenon gas blend, and specialized hardware to enable visualization of lung ventilation and, in development, gas exchange without ionizing radiation.

Polarean's primary competition comes from established lung imaging modalities like CT, nuclear medicine V/Q scans, and PET, which have entrenched clinical workflows but involve radiation. Within MRI, alternative research-stage techniques like fluorinated gas (19F) MRI or oxygen-enhanced MRI are in development, but Polarean holds a first-mover advantage with its FDA-approved hyperpolarized xenon agent.